NCT00751127已完成3 期
A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in the United States.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 268
- 试验地点
- 1
- 主要终点
- to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment.
研究概览
简要总结
PhXA41 is not inferior to timolol
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
- •Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilaterally must fulfill eligibility criteria for both eyes.)
- •IOP of 22mmHg or higher obtained during the pre-study period.
- •Patients currently not treated or on single-drug treatment for the elevated IOP are eligible after a medication free period (wash-out) of:
- •3 weeks for B-adrenergic antagonists
- •2 weeks for adrenergic agonists
- •5 days for cholinergics and oral carbonic anhydrase inhibitors.
排除标准
- •History of acute angle closure.
- •Severe trauma at any time.
- •Intraocular surgery or argon laser trabeculoplasty within 6 months.
- •Current use of contact lenses.
- •History of severe dry eye syndrome.
- •Ocular inflammation/infection with three months of inclusion.
- •Any condition preventing reliable applanation tonometry.
- •Unacceptable finding at pre-study ocular examination as specified in the Case Report Forms.
- •In Investigator regards monotherapy insufficient with respect to optic nerve head and/or visual field status.
- •Treatment of elevated IOP with any topical B-adrenergic antagonist regularly for a period longer than 3 months and/or treatment at any time during 6 months prior to study start.
- •Cardiac failure, sinus bradycardia, second and third degree of atrio-ventricular block.
- •Bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary disease.
- •Having participated in any other clinical study within the last month.
研究组 & 干预措施
Timolol
Active Comparator
干预措施: timolol (Drug)
PhXA41
Experimental
干预措施: PhXA41 (Drug)
结局指标
主要结局
to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment.
时间窗: 6 mos
次要结局
- to describe the IOP development throughout the study period and to follow the safety variables in the two treatment groups.(6 mos)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within ScandinaviaOpen Angle GlaucomaOcular HypertensionNCT00751062Pfizer's Upjohn has merged with Mylan to form Viatris Inc.267
已完成
3 期
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United KingdomOpen Angle GlaucomaOcular HypertensionNCT00751049Pfizer's Upjohn has merged with Mylan to form Viatris Inc.294
已完成
3 期
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In PatientsGlaucomaOpen-angle GlaucomaOcular HypertensionNCT00856622Pfizer's Upjohn has merged with Mylan to form Viatris Inc.436
已完成
3 期
A Study of Glaucoma or Ocular Hypertension in Patients Within the United StatesGlaucomaOcular HypertensionNCT00800267Pfizer's Upjohn has merged with Mylan to form Viatris Inc.418
已完成
4 期
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ GlaucomaGlaucoma, Open AngleOcular HypertensionNCT00140049Pfizer's Upjohn has merged with Mylan to form Viatris Inc.238